Panion reports successful safety study in dogs

Panion Animal Health AB develops a unique new gene therapy treatment for dogs with epilepsy. In spring 2018, a safety study in dogs was started under the lead of Associate Professor David Woldbye, Department of Neuroscience, University of Copenhagen. The clinical phase of the study is now finalised, and the first preliminary outcome can be reported.

All treated dogs have successfully completed the study without observable adverse reactions. Neurological examination of the dogs before and after the treatment showed no related changes, and the dogs exhibited ordinary behavior shortly after the gene therapy treatment procedure.

"We are extremely satisfied with the conduct and clinical results of the study. The observations confirm the good results that we have seen in earlier preclinical studies in 
rats and dogs." says CEO Anja Holm, "The many laboratory tests and samples will now be handled and analysed, and we expect that they support the direct observations. When a detailed report is ready in a couple of months, we will inform the market again."

The positive results from the safety study paves the way for conducting clinical trials in privately owned dogs that suffer from drug-refractory epilepsy. 1-2 % of all dogs worldwide have epilepsy and a third of these are not well controlled with medication. Panion's new gene therapy product is intended to cover the therapeutic gap for such dogs and their caring owners.

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion's CEO, Anja E. H. Holm, for publication on August 30 2018.


Anja E. H. Holm, CEO
+ 45-22 94 66 00 

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer

CombiGene lämnar ett offentligt uppköpserbjudande till innehavarna av aktier och teckningsoptioner av serie TO1 i Panion Animal Health

CombiGene AB (publ) ("CombiGene") har idag lämnat ett offentligt uppköpserbjudande till innehavarna av aktier ("Aktierna) och teckningsoptioner av serie TO1 med ISIN-kod SE0011205343 ("Teckningsoptionerna") i Panion Animal Health AB (publ) ("Panion" eller "Bolaget") att överlåta samtliga sina Aktier och Teckningsoptioner till CombiGene ("Erbjudandet"). Aktierna och Teckningsoptionerna är upptagna till handel på Spotlight Stock Market ("Spotlight").

Kommentar avseende revisorns anmärkning i publicerad årsredovisning för 2018

Angående revisorns anmärkning i årsredovisning 2018

Kallelse till årstämma i Panion Animal Health AB

Aktieägarna i Panion Animal Health AB (publ), 559018-4171, kallas härmed till årsstämma tisdagen den 23 april 2019 kl. 14.00 på Mazars SET Revisionsbyrå ABs kontor, Scheelevägen 17, i Lund.

PM Technical investigator meeting in Copenhagen

Panion develops a gene therapy treatment for dogs with epilepsy. The clinical trial in dogs with real epilepsy will take place in the large investigator clinic, Long Island Veterinary Specialists (LIVS) in New York, USA. The study procedures are advancing well in accordance with the plan. The vector material is produced and undergoing testing procedures.

New advisory board member

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90